Understand the source comparison
Comparison Table: NNMT Inhibitors and NAD+ Modulators
5-Amino-1MQ NNMT inhibition 7% reduction (11 days, mouse) High (IC50 1.2–3.8 μM) 28 days at 2–8°C Metabolic research, NAD+ pathway studies Nicotinamide Riboside (NR) NAD+ precursor supplementation Minimal direct effect on weight Non-selective 12 months at −20°
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 5-Amino-1MQ
- NNMT inhibition
- 7% reduction (11 days, mouse)
- High (IC50 1.2–3.8 μM)
- 28 days at 2–8°C
- Metabolic research, NAD+ pathway studies
- Nicotinamide Riboside (NR)
- NAD+ precursor supplementation
- Minimal direct effect on weight
- Non-selective
- 12 months at −20°C (dry)
- Ageing research, mitochondrial function
- Nicotinamide Mononucleotide (NMN)
- Variable (diet-dependent)
- 6 months at −20°C (dry)
- NAD+ replenishment studies
- Resveratrol
- SIRT1 activator (indirect)
- 5–8% reduction (high doses)
- Moderate (multiple targets)
- Stable in ethanol
- Polyphenol research, longevity models
- The bottom line: 5-Amino-1MQ peptide achieves targeted NNMT inhibition with reproducible metabolic effects in animal models, while NAD+ precursors like NR and NMN bypass NNMT entirely by supplying substrate directly. Selectivity and dosing simplicity favour 5-Amino-1MQ for studies focused on the NNMT-NAD+ axis specifically.